Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells

Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells

IntroductionGut microbiota plays a crucial role in the development and progression of nonalcoholic steatohepatitis (NASH) and associated hepatocellular carcinoma (HCC). Akkermansia muciniphila was reported to inhibit inflammation-associated cancer in the intestine. The anti-NASH ability of A. mucini...

Full description

Bibliographic Details
Main Authors:	Tao Li, Xinlong Lin, Binhai Shen, Wujian Zhang, Yangyang Liu, Hongbin Liu, Ye Wang, Lijun Zheng, Fachao Zhi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Immunology
Subjects:	cancer progression Akkermansia muciniphila tumor immune surveillance nonalcoholic fatty liver disease hepatocellular carcinoma - metabolic syndrome - non-alcoholic fatty liver disease (NAFLD) - non-alcoholic steatohepatitis - NASH-HCC
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1047570/full

Similar Items

Corrigendum: Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells
by: Tao Li, et al.
Published: (2023-11-01)

Corrigendum: Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells
by: Tao Li, et al.
Published: (2023-02-01)

Akkermansia Muciniphila Suppresses Non-alcoholic Steatohepatitis-associated Liver Cancer in Mice by Recovering Intestinal Barrier Function
by: ZHANG Wujian, et al.
Published: (2023-05-01)

Heat-Inactivated <i>Akkermansia muciniphila</i> Improves Gut Permeability but Does Not Prevent Development of Non-Alcoholic Steatohepatitis in Diet-Induced Obese Ldlr−/−.Leiden Mice
by: Martine C. Morrison, et al.
Published: (2022-02-01)

Liver Injury and Cell Survival in Non-Alcoholic Steatohepatitis Regulated by Sex-Based Difference through B Cell Lymphoma 6
by: Akihide Kamiya, et al.
Published: (2022-11-01)

Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis
by: Gregory Habig, et al.
Published: (2021-04-01)

Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated γδT17 cell and macrophage polarization
by: Yuqiu Han, et al.
Published: (2023-12-01)

Assessing whether serum ceruloplasmin promotes non-alcoholic steatohepatitis via regulating iron metabolism
by: Xia Ziqiang, et al.
Published: (2023-01-01)

Targeting MRG15 for the treatment of nonalcoholic steatohepatitis
by: Yao Zhang, et al.
Published: (2022-12-01)

The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review
by: Rodrigo Zamignan Carpi, et al.
Published: (2022-08-01)

Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report
by: Yeong Yeh Lee, et al.
Published: (2023-01-01)

Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease
by: Ye Eun Cho, et al.
Published: (2023-03-01)

MAFLD and CKD: An Updated Narrative Review
by: Alessandro Mantovani, et al.
Published: (2022-06-01)

Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients
by: Singh Deepak, et al.
Published: (2010-07-01)

Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma
by: Deniz Tümen, et al.
Published: (2022-12-01)

Preventative and Therapeutic Effects of Astaxanthin on NAFLD
by: Nor Hafiza Sayuti, et al.
Published: (2023-08-01)

Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role
by: Stefania De Lorenzo, et al.
Published: (2020-10-01)

Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice
by: Maria Guarino, et al.
Published: (2020-05-01)

Akkermansia muciniphila – multifunctional bacteria
by: Alicja Wosińska, et al.
Published: (2023-07-01)

Lipidomic identification of urinary extracellular vesicles for non-alcoholic steatohepatitis diagnosis
by: Qingfu Zhu, et al.
Published: (2022-07-01)

Symbiotic combination of Akkermansia muciniphila and inosine alleviates alcohol-induced liver injury by modulating gut dysbiosis and immune responses
by: Li Wei, et al.
Published: (2024-03-01)

Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action
by: Vanessa D. de Mello, et al.
Published: (2017-04-01)

Plasma Lipids Profile in the Prediction of Non-Alcoholic Steatohepatitis in Adults: A Case-Control Study
by: Georgios Kalopitas, et al.
Published: (2023-08-01)

Transcriptomic changes in liver transplant recipients with non-alcoholic steatohepatitis indicate dysregulation of wound healing
by: Diogo Pellegrina, et al.
Published: (2023-05-01)

Research progress of drugs targeting ferroptosis for the treatment of non-alcoholic fatty liver disease
by: HAO Dandan, ZHANG Lei, BAI Chunying
Published: (2023-08-01)

Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research
by: Christina-Maria Flessa, et al.
Published: (2022-12-01)

The Effect of Vitamin E Supplementation on Serum Aminotransferases in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis
by: Stamatina Vogli, et al.
Published: (2023-08-01)

Loss of hepatic VMP1 trapped VLDL in the bilayer of endoplasmic reticulum membrane
by: Hong-Min Ni, et al.
Published: (2023-06-01)

NAFLD: Mechanisms, Treatments, and Biomarkers
by: Fatiha Nassir
Published: (2022-06-01)

Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD)
by: Christoph Roderburg, et al.
Published: (2023-04-01)

Pathogenetic and clinical significance of the gut-liver microbiota axis
by: D. T. Dicheva, et al.
Published: (2022-05-01)

The Neutrophil-to-Lymphocyte Ratio as A Noninvasive Marker in Patients with Biopsy-Proven Non-Alcoholic Steatohepatitis
by: Mehmet Asıl, et al.
Published: (2016-12-01)

Current status of liver transplantation for non‐B non‐C liver cirrhosis and hepatocellular carcinoma
by: Takahiro Nishio, et al.
Published: (2023-01-01)

Silymarin and management of liver function in non-alcoholic steatohepatitis: a case report
by: Ahmed Hashem
Published: (2023-06-01)

Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations
by: CM Oneta
Published: (2002-09-01)

Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension?
by: Julia A. Golubeva, et al.
Published: (2023-09-01)

Non-alcoholic fatty liver disease: Definition and subtypes
by: Seul Ki Han, et al.
Published: (2023-02-01)

Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
by: Seul Ki Han, et al.
Published: (2023-07-01)

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
by: Yvonne Burmeister, et al.
Published: (2023-12-01)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
by: Laura Valenzuela-Vallejo, et al.
Published: (2023-05-01)